PRINCETON, NJ--(Marketwire - November 18, 2008) - Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women’s health products, announced today that after a successful end-of-Phase 2 meeting with the Food and Drug Administration (FDA), the company is moving forward with its pivotal Phase 3 program to support a NDA filing and marketing approval of AG200-15 with SKINFUSION™ technology. AG200-15 is an innovative, low-dose contraceptive patch that offers women a convenient, once-weekly form of birth control. AG200-15 will fulfill a large unmet need for a more convenient contraceptive alternative to the birth control pill.
